MX2018004091A - Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis. - Google Patents

Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis.

Info

Publication number
MX2018004091A
MX2018004091A MX2018004091A MX2018004091A MX2018004091A MX 2018004091 A MX2018004091 A MX 2018004091A MX 2018004091 A MX2018004091 A MX 2018004091A MX 2018004091 A MX2018004091 A MX 2018004091A MX 2018004091 A MX2018004091 A MX 2018004091A
Authority
MX
Mexico
Prior art keywords
prevention
treatment
antagonists
atopic dermatitis
present
Prior art date
Application number
MX2018004091A
Other languages
Spanish (es)
Inventor
Christophe Xavier Brys Reginald
Ernest Renó Vandeghinste Nick
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of MX2018004091A publication Critical patent/MX2018004091A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides antagonists of IL-17C for use in the treatment and/or prevention of atopic dermatitis and related conditions.
MX2018004091A 2015-10-05 2016-10-05 Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis. MX2018004091A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15188355 2015-10-05
PCT/EP2016/073776 WO2017060289A1 (en) 2015-10-05 2016-10-05 Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis

Publications (1)

Publication Number Publication Date
MX2018004091A true MX2018004091A (en) 2018-07-06

Family

ID=54256681

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004091A MX2018004091A (en) 2015-10-05 2016-10-05 Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis.

Country Status (13)

Country Link
US (1) US10604566B2 (en)
EP (1) EP3359161A1 (en)
JP (1) JP2018529704A (en)
KR (1) KR20180058806A (en)
CN (1) CN108135913A (en)
AU (1) AU2016335017A1 (en)
CA (1) CA3000779A1 (en)
HK (1) HK1257289A1 (en)
IL (1) IL258112A (en)
MX (1) MX2018004091A (en)
RU (1) RU2018114657A (en)
WO (1) WO2017060289A1 (en)
ZA (1) ZA201802501B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230203149A1 (en) 2017-09-25 2023-06-29 Morphosys Ag Treatment of atopic dermatitis
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
PT1076703E (en) 1998-05-15 2007-10-10 Genentech Inc Therapeutic uses of il-17 homologous polypeptides
US20040197306A1 (en) * 2000-05-24 2004-10-07 Gorman Daniel M. Mammalian receptor proteins; related reagents and methods
AU2002357060A1 (en) 2001-12-03 2003-06-17 Abgenix, Inc. Antibody categorization based on binding characteristics
CN101068835A (en) * 2004-10-18 2007-11-07 津莫吉尼蒂克斯公司 Soluble ZcytoR21, anti-ZcytoR21 antibodies and binding partners and methods of using in inflammation
BRPI0516603A (en) * 2004-10-18 2008-09-16 Zymogenetics Inc isolated soluble receptor, antibody or antibody fragment, and methods for treating an immune-mediated disease in a patient in need of such treatment, for reducing il-17c-mediated inflammation, for treating a mammal afflicted with an inflammatory disease, and to treat a pathological condition in a patient associated with zcytor21 activity
WO2007047738A1 (en) * 2005-10-18 2007-04-26 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
CA2666842A1 (en) * 2006-10-18 2008-04-24 Zymogenetics, Inc. Il-17c antagonists and methods of using the same
JPWO2009122748A1 (en) * 2008-04-04 2011-07-28 国立大学法人九州大学 Remedies for respiratory or allergic diseases
FR2938439B1 (en) * 2008-11-14 2013-03-01 Fabre Pierre Dermo Cosmetique EXTRACT OF AERIAL PARTS OF OATS HARVESTED BEFORE EPIAISON
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP2014530836A (en) 2011-10-19 2014-11-20 モルフォシス・アー・ゲー IL17C antagonist for the treatment of inflammatory disorders
RU2014121043A (en) * 2011-10-24 2015-12-10 Эббви Инк. BISPECIFIC IMMUNO-BINDING AGENTS AIMED AGAINST TNF AND IL-17
WO2013186236A1 (en) * 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses

Also Published As

Publication number Publication date
HK1257289A1 (en) 2019-10-18
US10604566B2 (en) 2020-03-31
EP3359161A1 (en) 2018-08-15
ZA201802501B (en) 2019-12-18
JP2018529704A (en) 2018-10-11
RU2018114657A3 (en) 2020-02-10
KR20180058806A (en) 2018-06-01
CA3000779A1 (en) 2017-04-13
RU2018114657A (en) 2019-11-07
US20180273614A1 (en) 2018-09-27
IL258112A (en) 2018-05-31
AU2016335017A1 (en) 2018-03-29
WO2017060289A1 (en) 2017-04-13
CN108135913A (en) 2018-06-08

Similar Documents

Publication Publication Date Title
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MX2019003623A (en) Compositions and methods for treating ophthalmic conditions.
MX2018006632A (en) Bicyclic inhibitors of pad4.
MY176855A (en) Anti-jagged1 antibodies and methods of use
MX2020005213A (en) Mk2 inhibitors and uses thereof.
NZ720769A (en) Anti-siglec-8 antibodies and methods of use thereof
MX2018006700A (en) Aza-benzimidazole inhibitors of pad4.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
PH12017501864A1 (en) Compositions and methods for treating autism
SG10202013034QA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
MX2017006019A (en) Apilimod for use in the treatment of melanoma.
IL263477A (en) Compositions and methods for the treatment or prevention of oxalate-related disorders
PH12017501022A1 (en) Compositions comprising 15-hepe and methods of treating or preventing fibrosis using same
MX2016016233A (en) Anti-lgr5 antibodies and uses thereof.
PH12016501838A1 (en) Compounds and their methods of use
MX2017013729A (en) Specific detection of clusterin isoforms.
IL251880A0 (en) Compositions for treating acute, post-operative, or chronic pain and methods of using the same
PL3122367T3 (en) Compositions based on saffron for the prevention and/or treatment of degenerative eye disorders.
MX2022011897A (en) Methods and compositions for treatment of cartilage damage and arthritis.
PL3197556T3 (en) Composition for the prevention and/or treatment of allergy symptoms
MX2015009153A (en) Use of alpha 7 nicotinic acetylcholine receptor agonists.
HK1257289A1 (en) Antagonists of il-17c for the treatment and/or prevention of atopic dermatitis
GB2581876B (en) Compositions for use in the treatment of endometrial disorder
DK3313207T3 (en) Compositions and methods for the treatment of malnutrition
EP3294339A4 (en) Methods and compositions for the treatment of arthritis